Literature DB >> 11170735

Further evidence for mitochondrial dysfunction in progressive supranuclear palsy.

D S Albers1, R H Swerdlow, G Manfredi, C Gajewski, L Yang, W D Parker, M F Beal.   

Abstract

Recent data from our laboratory have identified a role for mitochondrial dysfunction in the pathogenesis of progressive supranuclear palsy (PSP). To extend this finding, we measured key parameters of mitochondrial function in platelet-derived cytoplasmic hybrid (cybrid) cell lines expressing mitochondrial genes from patients with PSP. We observed significant decreases in aconitase activity, cellular ATP levels, and oxygen consumption in PSP cybrids as compared to control cybrids, further suggesting a contributory role of impaired mitochondrial energy metabolism in PSP, possibly due to genetic abnormalities of mitochondrial DNA. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170735     DOI: 10.1006/exnr.2000.7607

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  24 in total

Review 1.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

2.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Relationship between uric acid levels and progressive supranuclear palsy.

Authors:  David M Brody; Irene Litvan; Steve Warner; David E Riley; Deborah A Hall; Benzi M Kluger; David R Shprecher; Christopher R Cunningham
Journal:  Mov Disord       Date:  2016-02-18       Impact factor: 10.338

4.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

Review 5.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

6.  1-Methyl-4-phenylpyridinium-induced cell death via autophagy through a Bcl-2/Beclin 1 complex-dependent pathway.

Authors:  Chutikorn Nopparat; James E Porter; Manuchair Ebadi; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2013-12-11       Impact factor: 3.996

Review 7.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

Review 8.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 9.  Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases.

Authors:  Xiao-xia Dong; Yan Wang; Zheng-hong Qin
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

Review 10.  Mitochondrial medicine for neurodegenerative diseases.

Authors:  Heng Du; Shirley ShiDu Yan
Journal:  Int J Biochem Cell Biol       Date:  2010-01-11       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.